Niagen Bioscience, Inc. Common Stock NAGE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $31.47M+3.3% | $33.84M+16.2% | $33.99M+32.9% | $31.12M+36.8% | $30.48M+37.6% | ||
| $11.5M+3.1% | $12.14M+11.0% | $12.06M+29.1% | $10.89M+20.4% | $11.15M+28.2% | ||
| $19.98M+3.3% | $21.7M+19.3% | $21.93M+35.0% | $20.23M+47.7% | $19.33M+43.7% | ||
| 63.5%0.0pp | 64.1%+1.7pp | 64.5%+1.0pp | 65%+4.8pp | 63.4%+2.7pp | ||
| $1.48M+17.7% | $1.71M+30.0% | $1.8M+39.1% | $1.57M+19.1% | $1.26M-40.0% | ||
| $9.68M+19.2% | $10.41M+19.5% | $8.77M+24.5% | $8.21M+17.8% | $8.12M+20.4% | ||
| $7.24M+39.7% | $7.48M+609% | $7.13M+13.1% | $7.27M+28.3% | $5.18M-3.1% | ||
| $18.4M+26.4% | $17.62M+58.9% | $17.69M+20.9% | $17.04M+22.2% | $14.56M+2.6% | ||
| $1.58M-67.0% | $4.09M-42.5% | $4.24M+164% | $3.19M+1,344% | $4.77M+753% | ||
| 5%-10.6pp | 12.1%-12.3pp | 12.5%+6.2pp | 10.2%+11.4pp | 15.7%+19.0pp | ||
| $375K-18.3% | $338K-9.4% | $564K+104% | $552K+129% | $459K+92.1% | ||
| —— | $531.75K+88.4% | $531.75K+88.4% | $531.75K+88.4% | $531.75K+88.4% | ||
| $4.78M— | —— | —— | —— | $0— | ||
| $6.74M+28.8% | $4.42M-40.9% | $4.8M+156% | $3.74M+25,013% | $5.23M+1,163% | ||
| $417K+148% | $292K-4.3% | $222K— | $128K— | $168K— | ||
| $6.32M+24.8% | $4.13M-42.4% | $4.58M+144% | $3.61M+24,160% | $5.06M+1,129% | ||
| 20.1%+3.5pp | 12.2%-12.4pp | 13.5%+6.1pp | 11.6%+11.7pp | 16.6%+18.8pp | ||
| $0.07+16.7% | $0.05-44.4% | $0.05+150% | $0.04— | $0.06+700% | ||
| $0.08+14.3% | $0.05-44.4% | $0.06+200% | $0.05— | $0.07+800% | ||
| 84.6M+1.6% | 85.4M+9.4% | 86.6M+11.4% | 86.2M+14.1% | 83.2M+10.6% | ||
| 79.9M+2.7% | 79.2M+4.3% | 79.8M+5.0% | 79.2M+4.9% | 77.8M+3.4% | ||
| —— | $495.75K— | $495.75K— | $495.75K— | $495.75K— | ||
| $375K-18.3% | $338K-9.4% | $564K+104% | $552K+129% | $459K+92.1% | ||
| —— | -$53.5K— | -$53.5K— | -$53.5K— | -$53.5K— | ||
| $4.78M— | —— | —— | —— | $0— | ||
| $1.58M-67.0% | $4.09M-42.5% | $4.24M+164% | $3.19M+1,344% | $4.77M+753% | ||
| $1.87M-62.4% | $4.29M-41.3% | $4.43M+146% | $3.38M+7,000% | $4.97M+1,064% | ||
| $1.87M-62.4% | $4.29M-41.3% | $4.43M+146% | $3.38M+7,000% | $4.97M+1,064% | ||
| 5.9%-10.4pp | 12.7%-12.4pp | 13%+6.0pp | 10.9%+11.1pp | 16.3%+18.6pp | ||
| $1.58M-67.0% | $4.09M-42.5% | $4.24M+164% | $3.19M+1,344% | $4.77M+753% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Niagen Bioscience, Inc. Common Stock's revenue?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $130.4M in revenue over the trailing twelve months, up 20.8% year over year.
- Is Niagen Bioscience, Inc. Common Stock profitable?
- Niagen Bioscience, Inc. Common Stock reported $18.6M in net income over the trailing twelve months, a 14.3% net margin.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Gross margin is 64.3% and operating margin is 10.0%, with a 14.3% net margin.
- What is Niagen Bioscience, Inc. Common Stock's earnings per share?
- Niagen Bioscience, Inc. Common Stock's diluted EPS over the trailing twelve months is $0.21.
- Where does Niagen Bioscience, Inc. Common Stock's income statement data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
